BACKGROUND: Breast cancer cells can develop chemoresistance after prolonged exposure to cytotoxic drugs due to expression of the multi drug resistance (MDR) 1 gene. Type 2 cyclo-oxygenase (COX-2) inhibitors reverse the chemoresistance phenotype of a medullary thyroid carcinoma cell line, TT, and of a breast cancer cell line, MCF7, by inhibiting MDR1 expression and P-gp function. AIM: investigate the role of prostaglandin (PG) in modulating chemoresistance in MCF7 cells and to explore the involved intracellular mechanisms. METHODS: native and chemoresistant MCF7 cells were treated with PGH2 and resistance to Doxorubicin was tested in the presence or absence of COX-2 inhibitors. RESULTS: PGH2 restores resistance to the cytotoxic effects of Doxo, with concomitant nuclear translocation of the transcription factor NF-kappaB. CONCLUSIONS: COX-2 inhibitors prevent chemoresistance development in breast cancer cells by inhibiting P-gp expression and function by a mechanism that involves PGH2 generation and NF-kappaB activation.
BACKGROUND:Breast cancer cells can develop chemoresistance after prolonged exposure to cytotoxic drugs due to expression of the multi drug resistance (MDR) 1 gene. Type 2 cyclo-oxygenase (COX-2) inhibitors reverse the chemoresistance phenotype of a medullary thyroid carcinoma cell line, TT, and of a breast cancer cell line, MCF7, by inhibiting MDR1 expression and P-gp function. AIM: investigate the role of prostaglandin (PG) in modulating chemoresistance in MCF7 cells and to explore the involved intracellular mechanisms. METHODS: native and chemoresistant MCF7 cells were treated with PGH2 and resistance to Doxorubicin was tested in the presence or absence of COX-2 inhibitors. RESULTS:PGH2 restores resistance to the cytotoxic effects of Doxo, with concomitant nuclear translocation of the transcription factor NF-kappaB. CONCLUSIONS:COX-2 inhibitors prevent chemoresistance development in breast cancer cells by inhibiting P-gp expression and function by a mechanism that involves PGH2 generation and NF-kappaB activation.
Authors: Sanjeev Banerjee; Asfar S Azmi; Subhash Padhye; Marjit W Singh; Jubaraj B Baruah; Philip A Philip; Fazlul H Sarkar; Ramzi M Mohammad Journal: Pharm Res Date: 2010-04-27 Impact factor: 4.200
Authors: Daniela Molè; Erica Gentilin; Alejandro Ibañez-Costa; Teresa Gagliano; Manuel D Gahete; Federico Tagliati; Roberta Rossi; Maria Rosa Pelizzo; Giancarlo Pansini; Raúl M Luque; Justo P Castaño; Ettore degli Uberti; Maria Chiara Zatelli Journal: Endocrine Date: 2015-04-09 Impact factor: 3.633
Authors: Anika M S Hartz; Ralf G Rempe; Emma L B Soldner; Anton Pekcec; Juli Schlichtiger; Richard Kryscio; Bjoern Bauer Journal: FASEB J Date: 2019-10-29 Impact factor: 5.834